Literature DB >> 7448815

Thymidine kinase isoenzymes in human malignant lymphoma.

P H Ellims, M B Van der Weyden, G Medley.   

Abstract

The activities of thymidine kinase (TK) isoenzyme 1 and 2 were examined in extracts of human benign or malignant lymphoid tissue and correlated with degrees of morphological differentiation. TK2 activity occurred in peripheral blood lymphocytes of normal individuals, patients with chronic lymphocytic leukemia, or solid lymphoid tissue, exhibiting either nonneoplastic histological findings or those of diffuse well-differentiated lymphocytic lymphoma. TK1 activity occurred in solid, non-Hodgkin's lymphoma tissue, exhibiting lesser degrees of cellular differentiation, or in peripheral blood lymphocytes of patients with clinical aggressive chronic lymphocytic leukemia or lymphosarcoma leukemia. In non-Hodgkin's lymphoma tissue, the range of TK1 activities correlated broadly with the Rappaport classification, with higher values occurring in tissue exhibiting changes of diffuse poorly differentiated lymphocytic lymphoma or diffuse histiocytic lymphoma.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7448815

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  FLT-PET imaging of radiation responses in murine tumors.

Authors:  M H Pan; S C Huang; Y P Liao; D Schaue; C C Wang; D B Stout; J R Barrio; W H McBride
Journal:  Mol Imaging Biol       Date:  2008-08-01       Impact factor: 3.488

2.  Human thymidine kinase: purification and some properties of the TK1 isoenzyme from placenta.

Authors:  P H Ellims; T E Gan; L Cosgrove
Journal:  Mol Cell Biochem       Date:  1982-06-11       Impact factor: 3.396

3.  Molecular cloning and structural analysis of murine thymidine kinase genomic and cDNA sequences.

Authors:  P F Lin; H B Lieberman; D B Yeh; T Xu; S Y Zhao; F H Ruddle
Journal:  Mol Cell Biol       Date:  1985-11       Impact factor: 4.272

4.  Use of 3'-deoxy-3'-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors.

Authors:  You-Jung Yang; Jin-Sook Ryu; Seog-Young Kim; Seung Jun Oh; Ki Chun Im; Heuiran Lee; Sang-Wook Lee; Kyung Ja Cho; Gi-Jeong Cheon; Dae Hyuk Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01-11       Impact factor: 9.236

5.  Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer.

Authors:  D L Francis; D Visvikis; D C Costa; T H A Arulampalam; C Townsend; S K Luthra; I Taylor; P J Ell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-09       Impact factor: 9.236

6.  Transcriptional and posttranscriptional mechanisms regulate murine thymidine kinase gene expression in serum-stimulated cells.

Authors:  H B Lieberman; P F Lin; D B Yeh; F H Ruddle
Journal:  Mol Cell Biol       Date:  1988-12       Impact factor: 4.272

7.  Thymidine kinase isoenzymes in human acute monocytic leukemia.

Authors:  B Munch-Petersen; G Tyrsted
Journal:  Mol Cell Biochem       Date:  1985-03       Impact factor: 3.396

8.  Conditional Cytotoxic Anti-HIV Gene Therapy for Selectable Cell Modification.

Authors:  Himanshu Garg; Anjali Joshi
Journal:  Hum Gene Ther       Date:  2016-03-30       Impact factor: 5.695

9.  The uptake of 3'-deoxy-3'-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels.

Authors:  Henryk Barthel; Meg Perumal; John Latigo; Qimin He; Frank Brady; Sajinder K Luthra; Pat M Price; Eric O Aboagye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-04       Impact factor: 9.236

10.  Thymidine kinase activities in mononuclear leukocytes and serum from breast cancer patients.

Authors:  P G McKenna; K L O'Neill; W P Abram; B M Hannigan
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.